[go: up one dir, main page]

MX2020007389A - Polipéptidos de unión al receptor de transferrina y usos de estos. - Google Patents

Polipéptidos de unión al receptor de transferrina y usos de estos.

Info

Publication number
MX2020007389A
MX2020007389A MX2020007389A MX2020007389A MX2020007389A MX 2020007389 A MX2020007389 A MX 2020007389A MX 2020007389 A MX2020007389 A MX 2020007389A MX 2020007389 A MX2020007389 A MX 2020007389A MX 2020007389 A MX2020007389 A MX 2020007389A
Authority
MX
Mexico
Prior art keywords
tfr
polypeptide
binding
transferrin receptor
binding site
Prior art date
Application number
MX2020007389A
Other languages
English (en)
Inventor
Joy Yu Zuchero
Zachary K Sweeney
Mark S Dennis
Mihalis Kariolis
Adam P Silverman
Wanda Kwan
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of MX2020007389A publication Critical patent/MX2020007389A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción se relaciona, en términos generales, con dímeros de polipéptidos Fc que contienen un sitio de unión al receptor de transferrina no natural (TfR), que no disminuyen considerablemente los reticulocitos in vivo, pero que conservan la unión al receptor de Fc? (Fc?R). La presente descripción se relaciona también con un dímero de polipéptidos Fc que contiene un sitio no natural que se une específicamente a TfR en uno de los polipéptidos Fc; una modificación o modificaciones en el polipéptido Fc que contiene el sitio de unión a TfR que reduce la unión a Fc?R cuando se une a TfR, donde el otro polipéptido Fc no contiene un sitio de unión a TfR pero conserva la unión a Fc?R.
MX2020007389A 2018-01-10 2019-01-10 Polipéptidos de unión al receptor de transferrina y usos de estos. MX2020007389A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862615914P 2018-01-10 2018-01-10
US201862631281P 2018-02-15 2018-02-15
US201862682639P 2018-06-08 2018-06-08
US201862721275P 2018-08-22 2018-08-22
PCT/US2019/012990 WO2019140050A1 (en) 2018-01-10 2019-01-10 Transferrin receptor-binding polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
MX2020007389A true MX2020007389A (es) 2020-10-14

Family

ID=65441044

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007389A MX2020007389A (es) 2018-01-10 2019-01-10 Polipéptidos de unión al receptor de transferrina y usos de estos.

Country Status (15)

Country Link
US (1) US20210130485A1 (es)
EP (1) EP3737701A1 (es)
JP (3) JP2021510162A (es)
KR (1) KR102720600B1 (es)
CN (1) CN111741977A (es)
AR (1) AR114077A1 (es)
AU (1) AU2019207735A1 (es)
BR (1) BR112020013921A2 (es)
CA (1) CA3088157A1 (es)
CO (1) CO2020009827A2 (es)
IL (1) IL275969A (es)
MX (1) MX2020007389A (es)
SG (1) SG11202006420TA (es)
TW (1) TW201934573A (es)
WO (1) WO2019140050A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS63818B1 (sr) 2017-02-17 2023-01-31 Denali Therapeutics Inc Konstruisani polipeptidi za vezivanje za receptor transferina
MA50746A (fr) 2017-10-02 2020-08-12 Denali Therapeutics Inc Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive
CN109705211B (zh) 2017-10-26 2020-08-18 苏州复融生物技术有限公司 一种IgG1 Fc单体及其应用
WO2020037150A2 (en) * 2018-08-16 2020-02-20 Denali Therapeutics Inc. Engineered bispecific proteins
CN113614110B (zh) 2019-02-20 2025-03-25 戴纳立制药公司 抗trem2抗体及其使用方法
CA3165846A1 (en) 2019-12-23 2021-07-01 Denali Therapeutics Inc. Progranulin variants
MX2022008582A (es) 2020-01-13 2022-08-10 Denali Therapeutics Inc Anticuerpos anti-trem2 y metodos para utilizarlos.
CN116916947A (zh) 2020-10-14 2023-10-20 戴纳立制药公司 包含磺基葡糖胺磺基水解酶的融合蛋白和其方法
CN112341538A (zh) * 2020-10-27 2021-02-09 苏州复融生物技术有限公司 一种Fc单体多肽及其应用
IL308004A (en) * 2021-05-05 2023-12-01 Univ Tennessee Res Found Peptide-fc fusions for treating amyloid disorders
JP2024527324A (ja) * 2021-07-01 2024-07-24 デナリ セラピューティクス インコーポレイテッド トランスフェリン受容体を標的とするオリゴヌクレオチド抱合体
CN115873127A (zh) * 2021-11-26 2023-03-31 深圳科兴药业有限公司 重组长效人生长激素融合蛋白及其制备方法和用途
CA3242959A1 (en) * 2021-12-17 2025-02-26 Denali Therapeutics Inc. POLYPEPTIDE ENGINEERING, LIBRARIES AND ENGINEERED POLYPEPTIDES FOR CD98 HEAVY CHAIN LINK AND TRANSFERRINE RECEIVER
EP4547716A2 (en) * 2022-07-01 2025-05-07 Denali Therapeutics Inc. Transferrin receptor binding molecule conjugates for delivery of oligonucleotides to cells
JP2025525791A (ja) 2022-07-29 2025-08-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 抗ＴｆＲ：ペイロード融合体及びそれを使用する方法
JP2025525792A (ja) 2022-07-29 2025-08-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド トランスフェリン受容体１に対して再標的化されるウイルス粒子
WO2024026474A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
EP4561348A2 (en) 2022-07-29 2025-06-04 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a modified transferrin receptor locus
EP4634218A2 (en) * 2022-12-16 2025-10-22 Denali Therapeutics Inc. Methods and compositions related to engineered transferrin receptor-binding molecules
CN120958020A (zh) 2023-03-24 2025-11-14 戴纳立制药公司 Aβ靶向蛋白和使用方法
US20250049896A1 (en) 2023-07-28 2025-02-13 Regeneron Pharmaceuticals, Inc. Anti-tfr:acid sphingomyelinase for treatment of acid sphingomyelinase deficiency
US20250041455A1 (en) 2023-07-28 2025-02-06 Regeneron Pharmaceuticals, Inc. Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981217A (en) * 1995-12-11 1999-11-09 Mayo Foundation For Medical Education And Research DNA encoding TGF-β inducible early factor-1 (TIEF-1), a gene expressed by osteoblasts
DE60139788D1 (de) * 2000-09-06 2009-10-15 Aventis Pharma Sa Verfahren und zusammensetzungen für amyloidosis-verbundene krankheiten
AU2003262886A1 (en) * 2002-08-30 2004-03-19 Biorexis Pharmaceutical Corporation Modified transferrin fusion proteins comprising duplicate transferrin amino or carboxy terminal domains
AU2004204494B2 (en) * 2003-01-09 2011-09-29 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
WO2005077981A2 (en) * 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
CA2658654A1 (en) * 2006-07-24 2008-01-31 Biorexis Pharmaceutical Corporation Exendin fusion proteins
EP3594239B1 (en) * 2012-05-21 2024-10-30 F. Hoffmann-La Roche AG Methods for improving safety of blood-brain barrier transport
PL3594240T3 (pl) * 2013-05-20 2024-04-02 F. Hoffmann-La Roche Ag Przeciwciała przeciwko receptorowi transferyny i sposoby ich zastosowania
WO2016077806A1 (en) * 2014-11-13 2016-05-19 AskGene Pharma, Inc. Fusion proteins with dual receptor agonist activities
EP3221362B1 (en) * 2014-11-19 2019-07-24 F.Hoffmann-La Roche Ag Anti-transferrin receptor antibodies and methods of use
MY187033A (en) * 2015-06-24 2021-08-27 Japan Chem Res Anti-human transferrin receptor antibody permeating blood-brain barrier
AR106189A1 (es) * 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
CN110520440A (zh) * 2017-02-17 2019-11-29 戴纳立制药公司 抗τ抗体及其使用方法
US10457717B2 (en) * 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides
RS63818B1 (sr) * 2017-02-17 2023-01-31 Denali Therapeutics Inc Konstruisani polipeptidi za vezivanje za receptor transferina
WO2018210898A1 (en) * 2017-05-18 2018-11-22 F. Hoffmann-La Roche Ag Reduction of application-related side reaction of a therapeutic antibody
WO2018237338A1 (en) * 2017-06-23 2018-12-27 Denali Therapeutics Inc. Anti-alpha-synuclein antibodies and methods of use thereof

Also Published As

Publication number Publication date
IL275969A (en) 2020-08-31
CN111741977A (zh) 2020-10-02
JP2026010691A (ja) 2026-01-22
BR112020013921A2 (pt) 2020-12-01
US20210130485A1 (en) 2021-05-06
CO2020009827A2 (es) 2020-10-30
AR114077A1 (es) 2020-07-15
WO2019140050A1 (en) 2019-07-18
TW201934573A (zh) 2019-09-01
KR20200119251A (ko) 2020-10-19
AU2019207735A1 (en) 2020-07-23
JP2024016195A (ja) 2024-02-06
EP3737701A1 (en) 2020-11-18
SG11202006420TA (en) 2020-08-28
KR102720600B1 (ko) 2024-10-21
JP2021510162A (ja) 2021-04-15
CA3088157A1 (en) 2019-07-18

Similar Documents

Publication Publication Date Title
MX2020007389A (es) Polipéptidos de unión al receptor de transferrina y usos de estos.
CL2021000291A1 (es) Constructos de anticuerpos para cldn18.2 y cd3
AR091735A1 (es) Complejo de factor viii con xten y proteina factor de von willebrand (vwf) y usos del mismo
ES2686327T3 (es) Moléculas de unión a antígeno biespecíficas
EA202190542A1 (ru) Сконструированные биспецифические белки
MX2021015880A (es) Fragmentos de unión al antígeno cd3 y composiciones que comprenden los mismos.
NZ756763A (en) Engineered transferrin receptor binding polypeptides
MX2020011828A (es) Anticuerpos anti proteina alfa reguladora de se?ales (sirpa) y metodos de uso de los mismos.
MX380658B (es) Variantes de region fc con union mejorada de la proteina a.
MX2020002977A (es) Agonistas de receptor de peptido similar al glucagon tipo 1 y usos de los mismos.
EP4282483A3 (en) Methods
CO5720212A1 (es) Composicion de anticuerpo her2
AR094149A1 (es) Proteinas multifuncion que comprenden chm de clase i multivalente unido mediante disulfuro
GT200900229A (es) Coagonistas de receptor de glucagón/glp-1
EP4249097A3 (en) Fc binding proteins with cysteine in the c-terminal helical region
MX2018005399A (es) Nuevo polipeptido con afinidad por pd-l1.
MX2024007263A (es) Modificación de polipéptidos, bibliotecas y cadena pesada cd98 modificada y polipéptidos de unión al receptor de transferrina.
CL2021003561A1 (es) Anticuerpos contra caix con afinidad reducida por el receptor de fc neonatal
MX2022009915A (es) Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
MX2023001262A (es) Polipéptidos inhibidores del ligando 1 de muerte programada que prolongan la vida media del suero.
PE20190966A1 (es) Factor viii direccionado a los globulos rojos y metodo para su uso
CL2023001310A1 (es) Construcciones polipeptídicas que se unen selectivamente a cldn6 y cd3
AR117343A1 (es) AGENTES DE UNIÓN REVERSIBLE PARA ANTICUERPOS ANTI-FACTOR XI / XIa Y USOS DE LOS MISMOS
NZ788210A (en) Neonatal fc receptor binding affimers
NZ757598A (en) Il-1r-i binding polypeptide